Stock Analysis, Dividends, Split History

EYEG / Eyegate Pharmaceuticals Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)22.07
Enterprise Value ($M)9.98
Book Value ($M)13.55
Book Value / Share0.31
Price / Book1.66
NCAV ($M)7.72
NCAV / Share0.18
Price / NCAV2.98
Share Statistics
Common Stock Shares Outstanding 17,257,255
Common Shares Outstanding 17,257,255
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)6.86
Return on Assets (ROA)-1.36
Return on Equity (ROE)40.12
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio3.21
Income Statement (mra) ($M)
Sales Revenue Net407,518.00
Net Income-13.22
Cash Flow Statement (mra) ($M)
Cash From Operations-6.47
Cash from Investing-0.04
Cash from Financing-0.04
Identifiers and Descriptors
Central Index Key (CIK)1372514

Split History

Stock splits are used by Eyegate Pharmaceuticals Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate

2018-07-27 seekingalpha
Discussion: Biohaven Pharmaceutical Holding Company (BHVN) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (‘AD). Patient enrollment is expected to begin shortly. Following details of the study plan have been shared by the company. During the 48-week trial period, the 292-subject study will be randomized between trigriluzole and placebo. (10-2)

Reader Inquiry: Time To Buy EyeGate Pharmaceuticals?

2018-05-18 seekingalpha
Shares of fallen nearly 70% year to date but appear to be ready to fill the gap back to the psychologically important $1 level. (22-3)

Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data

2018-04-16 seekingalpha
Intercept Pharmaceuticals (ICPT) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis. (143-3)

Office Depot, Dominion Energy Fall into Friday’s 52-Week Low Club

2018-04-13 247wallst
April 13, 2018: Here are four stocks trading with heavy volume among 52 equities making new 52-week lows in Friday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by about 9 to 5. (19-0)

Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback

2018-04-10 seekingalpha
Today we will discuss Acadia Pharmaceuticals (NASDAQ:ACAD), which has fallen sharply on a CNN report that raised concerns about the Nuplazid’s safety. (210-4)

Silicon Investor Message Boards

This table lists all message boards related to EYEG / Eyegate Pharmaceuticals Inc. on message board site Silicon Investor.

EYES Second Sight-Eyeglasses for the Blind help them see EYES Second Sight-Eyeglasses for the Blind help them see EYES Second Sight-Eyeglasses for the Blind help them see
CUSIP: 30233M107